

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known

(Use as many sheets as necessary)

Sheet	1	of	2
-------	---	----	---

Application Number	10/517,869
Filing Date	Oct. 12, 2005
First Named Inventor	Lehmann, Anders
Art Unit	1614
Examiner Name	Spivack, Phyllis G
Attorney Docket Number	1103326-0946

[illegible]

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.†	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Application of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T S
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				
		WO 98/11885	Mar. 26, 1998	Andrews et al.		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPPEP 699. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind document by the appropriate symbols as indicated on the document under WIPO Standard ST.15 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/517,869
Filing Date	Oct. 12, 2005
First Named Inventor	Lehmann, Anders
Art Unit	1614
Examiner Name	Spivack, Phyllis G.
Attorney Docket Number	1103326-0946

Sheet	2	of	2
-------	---	----	---

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		WISE ET AL., "Calcium sensing properties of the GABA _B receptor", <i>Neuropharmacology</i> , vol. 38 (1999), pp. 1647-1656.	
		BORDI ET AL., "Group I metabotropic glutamate receptors: implications for brain diseases", <i>Progress in Neurobiology</i> vol. 59, (1999), pp. 55-79.	
		SCHMIDT ET AL., "A new phospholipase-C-calcium signaling pathway mediated by cyclic AMP and a Rap GTPase", <i>Nature Cell Biology</i> , vol. 3 (2001), pp. 1020-1024; and supplementary information, page 1.	
		SPOOREN ET AL., "Effects of the prototypical mGlu ₅ receptor antagonist 2-methyl-6-(phenylethynyl)-pyridine on rotarod, locomotor activity and rotational responses in unilateral 6-OHDA-lesioned rats", <i>European Journal of Pharmacology</i> , vol. 406 (2000), pp. 403-410.	
		SPOOREN ET AL., "Novel allosteric antagonists shed light on mglu ₅ receptors and CNS disorders", <i>TRENDS in Pharmacological Sciences</i> , vol. 22, no. 7 (2001), pp. 331-337.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.96. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.